Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Net Margin (2016 - 2026)

United Therapeutics' Net Margin history spans 17 years, with the latest figure at 46.1% for Q4 2025.

  • On a quarterly basis, Net Margin rose 516.0% to 46.1% in Q4 2025 year-over-year; TTM through Dec 2025 was 41.94%, a 40.0% increase, with the full-year FY2025 number at 41.94%, up 40.0% from a year prior.
  • Net Margin hit 46.1% in Q4 2025 for United Therapeutics, up from 42.36% in the prior quarter.
  • Over the last five years, Net Margin for UTHR hit a ceiling of 51.94% in Q1 2022 and a floor of 7.47% in Q1 2021.
  • Historically, Net Margin has averaged 38.21% across 5 years, with a median of 40.75% in 2024.
  • Biggest five-year swings in Net Margin: tumbled -3118bps in 2021 and later soared 4447bps in 2022.
  • Tracing UTHR's Net Margin over 5 years: stood at 27.02% in 2021, then dropped by -1bps to 26.88% in 2022, then soared by 31bps to 35.32% in 2023, then rose by 16bps to 40.94% in 2024, then increased by 13bps to 46.1% in 2025.
  • Business Quant data shows Net Margin for UTHR at 46.1% in Q4 2025, 42.36% in Q3 2025, and 38.76% in Q2 2025.